A Phase 3 interventional study of eculizumab in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 69 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-23.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Neuromyelitis Optica by AstraZeneca — 3 open to participants now, 5 under way, 3 of them phase 3. Neuromyelitis Optica · AstraZeneca.
Among the 11 studies in Neuromyelitis Optica by AstraZeneca, this one is one of 2 that started in 2015, is one of 5 in phase 3, and was the 2nd registered.
178 studies on the registry are indexed under Neuromyelitis Optica; 78 are open to participants now.
Browse Neuromyelitis Optica studies →3 of the 11 studies in Neuromyelitis Optica by AstraZeneca are open now, in 11 countries. Recruiting first, the newest first:
Alexion Pharmaceuticals, Inc. · Sites in China
Ages 18–130
Alexion Pharmaceuticals, Inc. · Sites in United States, Australia, France and 4 more countries
Women only
Alexion Pharmaceuticals, Inc. · Sites in United States, Argentina, Canada and 5 more countries
Ages 18+
By country, each count listing its studies:
Of the 50 Neuromyelitis Optica studies recruiting now, 29 (58%) set no upper age limit and 16 (32%) stop at 75 or younger; 11 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 8
First in 2014; this study’s year is marked. 2 started in 2015.
This study's enrollment of 119 is above the median of 29 across 108 interventional studies indexed under Neuromyelitis Optica.
Median enrollment 40 across the 8 interventional studies, 75 across the 3 observational. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Alexion Pharmaceuticals, Inc., one of the names counted as AstraZeneca. Under that name alone:
Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
1 of the studies in Neuromyelitis Optica by AstraZeneca that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06724809Phase 3Alexion Pharmaceuticals, Inc.Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD | 2026-12-07 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Neuromyelitis Optica by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether eculizumab long-term use is safe and effective in patients with relapsing NMO.
This study is an open label extension study to confirm the long term safety and efficacy of eculizumab in subjects with relapsing NMO who have completed the initial double-blind, randomized, placebo-controlled trial ECU-NMO-301.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eculizumab intravenous infusion every two weeks.
Biological: eculizumab
Also known as: Soliris
Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Treatment-emergent adverse events (TEAEs) were defined as an AE with onset on or after the first study drug dose in Study ECU-NMO-302. A serious adverse event (SAE) was defined as an untoward medical occurrence that at any dose either results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event. A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.
Time frame: Baseline up to end of study (up to 6.5 years)
Number of Participants With At Least 1 Post Baseline Columbia-Suicide Severity Rating Scale (C-SSRS) Assessment (Suicide-Related Thoughts or Behaviours) Abnormality
The C-SSRS is a validated questionnaire to capture occurrence, severity, and frequency of suicide-related thoughts and behaviours, and has a binary response (yes/no). Suicidal Ideation: a "yes" answer to any one of 5 suicidal ideation questions: Wish to be Dead; Non-specific Active Suicidal Thoughts; Active Suicidal Ideation with Any Methods (Not Planned) without Intent to Act; Active Suicidal Ideation with Some Intent to Act, without Specific Plan; and Active Suicidal Ideation with Specific Plan and Intent. Suicidal Behaviour: a "yes" answer to any of 5 suicidal behaviour questions: Preparatory Acts or Behaviour, Aborted Attempt, Interrupted Attempt, Actual Attempt (non-fatal), and Completed Suicide. Suicidal Ideation or Behaviour: a "yes" answer to the following question: Self-injurious behaviour without suicidal intent.
Time frame: Baseline up to end of study (up to 6.5 years)
Number of Participants With An On-trial Relapse as Determined by The Treating Physician
An On-trial Relapse was defined as a new onset of neurologic symptoms or worsening of existing neurologic symptoms with an objective change (clinical sign) on neurologic examination that persisted for more than 24 hours as confirmed by the treating physician.
Time frame: Baseline up to end of study (up to 6.5 years)
On-Trial Annualized Relapse Rate (ARR) as Determined by The Treating Physician
The On-trial ARR was computed as the total number of relapses divided by the total number of participant years in the study period.
Time frame: Baseline up to end of study (up to 6.5 years)
Change From Baseline in Expanded Disability Status Scale (EDSS) Score
Disease-related disability was measured by the EDSS. The EDSS quantifies disability in 8 Functional Systems (FS) and allows neurologists to assign a Functional System Score (FSS) in each of these. The Functional Systems are pyramidal, cerebellar, brainstem, sensory, bowel and bladder, visual, cerebral, and other. The EDSS is an ordinal clinical rating scale that ranges from 0 (normal neurologic examination) to 10 (death) in half-point increments. A decrease in score indicates improvement. Baseline was defined as the last available assessment prior to the first study drug infusion in Study ECU-NMO-302.
Time frame: Baseline, Weeks 52, 104 and 156
Change From Baseline in Modified Rankin Scale (mRS) Score
Disease-related disability was measured by the mRS score. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered from a neurological disability. The scale ranges from 0 (no symptoms at all) to 6 (death) in whole-point increments. A decrease in score indicates improvement. Baseline was defined as the last available assessment prior to the first study drug infusion in Study ECU-NMO-302.
Time frame: Baseline, Weeks 52, 104 and 156
Change From Baseline in Hauser Ambulation Index (HAI) in Participants With Abnormal Baseline Ambulatory Function
The HAI evaluates gait and was used to assess the time and effort used by the participant to walk 25 feet (8 meters). The scale ranges from 0 to 9, with 0 being the best score (asymptomatic; fully active) and 9 being the worst (restricted to wheelchair; unable to transfer self independently). A decrease in score indicates improvement. Baseline is defined as the last available assessment prior to the first study drug infusion in Study ECU-NMO-302.
Time frame: Baseline, Weeks 52, 104 and 156
Change From Baseline in European Quality of Life (EuroQoL) 5-Dimension Visual Analog Scale (EQ-5D VAS) Health Status Score
The EQ-5D is a generic, standardized participant self-administered health status instrument. EQ-5D general health status can also be measured by a visual analog scale (EQ-5D VAS). EQ-5D-VAS recorded the participant's self-rated health on a vertical visual analog scale (VAS) that allowed the participants to indicate their health state that ranged from 0 (worst imaginable) to 100 (best imaginable). Baseline is defined as the last available assessment prior to the first study drug infusion in Study ECU-NMO-302.
Time frame: Baseline, Weeks 52, 104 and 156
Change From Baseline in Kurtzke Visual Functional System Scores (FSS) in Participants With Abnormal Baseline Visual Function
The EDSS assesses multiple Kurtzke functional systems in the context of a standard neurological exam, including visual function. The visual score ranges from 0 to 6. A score of 0 implies the participant has normal visual function. Higher scores represent worse disability. Baseline is defined as the last available assessment prior to the first study drug infusion in Study EC-NMO-302.
Time frame: Baseline, Weeks 52, 104 and 156
| Milestone | Placebo/Eculizumab | Eculizumab/Eculizumab |
|---|---|---|
| Started | 41 | 78 |
| Received at least 1 dose of study drug | 41 | 78 |
| Completed | 41 | 78 |
| Not completed | 0 | 0 |
| Milestone | Placebo/Eculizumab | Eculizumab/Eculizumab |
|---|---|---|
| Started | 41 | 78 |
| Received at least 1 dose of study drug | 41 | 78 |
| Completed | 32 | 64 |
| Not completed | 9 | 14 |
| Withdrew: Other than specified | 2 | 4 |
| Withdrew: Withdrawal by subject | 4 | 5 |
| Withdrew: Pregnancy | 0 | 2 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Adverse event | 2 | 1 |
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Treatment-emergent adverse events (TEAEs) were defined as an AE with onset on or after the first study drug dose in Study ECU-NMO-302. A serious adverse event (SAE) was defined as an untoward medical occurrence that at any dose either results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event. A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.
| Participants | Placebo/Eculizumab | Eculizumab/Eculizumab |
|---|---|---|
| TEAEs | 41 | 70 |
| SAEs | 14 | 26 |
The C-SSRS is a validated questionnaire to capture occurrence, severity, and frequency of suicide-related thoughts and behaviours, and has a binary response (yes/no). Suicidal Ideation: a "yes" answer to any one of 5 suicidal ideation questions: Wish to be Dead; Non-specific Active Suicidal Thoughts; Active Suicidal Ideation with Any Methods (Not Planned) without Intent to Act; Active Suicidal Ideation with Some Intent to Act, without Specific Plan; and Active Suicidal Ideation with Specific Plan and Intent. Suicidal Behaviour: a "yes" answer to any of 5 suicidal behaviour questions: Preparatory Acts or Behaviour, Aborted Attempt, Interrupted Attempt, Actual Attempt (non-fatal), and Completed Suicide. Suicidal Ideation or Behaviour: a "yes" answer to the following question: Self-injurious behaviour without suicidal intent.
| Participants | Placebo/Eculizumab | Eculizumab/Eculizumab |
|---|---|---|
| Suicidal Ideation | 4 | 5 |
| Suicidal Behavior | 0 | 1 |
| Suicidal Ideation or Behavior | 4 | 5 |
An On-trial Relapse was defined as a new onset of neurologic symptoms or worsening of existing neurologic symptoms with an objective change (clinical sign) on neurologic examination that persisted for more than 24 hours as confirmed by the treating physician.
| Participants | Placebo/Eculizumab | Eculizumab/Eculizumab |
|---|---|---|
| Number of Participants With An On-trial Relapse as Determined by The Treating Physician | 5 | 8 |
The On-trial ARR was computed as the total number of relapses divided by the total number of participant years in the study period.
| relapses/years on study | Placebo/Eculizumab | Eculizumab/Eculizumab |
|---|---|---|
| On-Trial Annualized Relapse Rate (ARR) as Determined by The Treating Physician | 0.128 ± 0.4576 | 0.061 ± 0.2186 |
Disease-related disability was measured by the EDSS. The EDSS quantifies disability in 8 Functional Systems (FS) and allows neurologists to assign a Functional System Score (FSS) in each of these. The Functional Systems are pyramidal, cerebellar, brainstem, sensory, bowel and bladder, visual, cerebral, and other. The EDSS is an ordinal clinical rating scale that ranges from 0 (normal neurologic examination) to 10 (death) in half-point increments. A decrease in score indicates improvement. Baseline was defined as the last available assessment prior to the first study drug infusion in Study ECU-NMO-302.
| units on a scale | Placebo/Eculizumab | Eculizumab/Eculizumab |
|---|---|---|
| Baseline | 4.34 ± 1.879 | 3.97 ± 1.736 |
| Change from Baseline at Week 52 | -0.24 ± 0.721 | 0.01 ± 0.571 |
| Change from Baseline at Week 104 | -0.39 ± 0.830 | -0.11 ± 0.536 |
| Change from Baseline at Week 156 | -0.38 ± 1.003 | -0.38 ± 1.057 |
Disease-related disability was measured by the mRS score. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered from a neurological disability. The scale ranges from 0 (no symptoms at all) to 6 (death) in whole-point increments. A decrease in score indicates improvement. Baseline was defined as the last available assessment prior to the first study drug infusion in Study ECU-NMO-302.
| units on a scale | Placebo/Eculizumab | Eculizumab/Eculizumab |
|---|---|---|
| Baseline | 2.39 ± 1.358 | 1.88 ± 1.269 |
| Change from Baseline at Week 52 | -0.27 ± 0.932 | -0.04 ± 0.458 |
| Change from Baseline at Week 104 | -0.41 ± 1.182 | -0.14 ± 0.543 |
| Change from Baseline at Week 156 | -0.62 ± 1.446 | -0.31 ± 0.602 |
The HAI evaluates gait and was used to assess the time and effort used by the participant to walk 25 feet (8 meters). The scale ranges from 0 to 9, with 0 being the best score (asymptomatic; fully active) and 9 being the worst (restricted to wheelchair; unable to transfer self independently). A decrease in score indicates improvement. Baseline is defined as the last available assessment prior to the first study drug infusion in Study ECU-NMO-302.
| units on a scale | Placebo/Eculizumab | Eculizumab/Eculizumab |
|---|---|---|
| Baseline | 2.83 ± 2.123 | 2.35 ± 2.257 |
| Change from Baseline at Week 52 | -0.44 ± 1.132 | 0.08 ± 0.816 |
| Change from Baseline at Week 104 | -0.57 ± 1.777 | 0.07 ± 1.033 |
| Change from Baseline at Week 156 | -1.08 ± 1.706 | 0.07 ± 1.269 |
The EQ-5D is a generic, standardized participant self-administered health status instrument. EQ-5D general health status can also be measured by a visual analog scale (EQ-5D VAS). EQ-5D-VAS recorded the participant's self-rated health on a vertical visual analog scale (VAS) that allowed the participants to indicate their health state that ranged from 0 (worst imaginable) to 100 (best imaginable). Baseline is defined as the last available assessment prior to the first study drug infusion in Study ECU-NMO-302.
| units on a scale | Placebo/Eculizumab | Eculizumab/Eculizumab |
|---|---|---|
| Baseline | 62.00 ± 22.012 | 72.27 ± 20.941 |
| Change from Baseline at Week 52 | 2.22 ± 13.294 | -0.78 ± 12.388 |
| Change from Baseline at Week 104 | 0.05 ± 18.867 | 1.28 ± 11.295 |
| Change from Baseline at Week 156 | 11.00 ± 19.374 | -4.13 ± 18.421 |
The EDSS assesses multiple Kurtzke functional systems in the context of a standard neurological exam, including visual function. The visual score ranges from 0 to 6. A score of 0 implies the participant has normal visual function. Higher scores represent worse disability. Baseline is defined as the last available assessment prior to the first study drug infusion in Study EC-NMO-302.
| units on a scale | Placebo/Eculizumab | Eculizumab/Eculizumab |
|---|---|---|
| Baseline | 3.75 ± 2.030 | 3.60 ± 2.031 |
| Change from Baseline at Week 52 | -0.08 ± 0.392 | -0.06 ± 0.569 |
| Change from Baseline at Week 104 | -0.13 ± 0.352 | -0.10 ± 0.651 |
| Change from Baseline at Week 156 | 0.00 ± 0.000 | -0.29 ± 0.994 |
Collected over Baseline up to end of study (up to 6.5 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo/Eculizumab | 0/41 (0%) | 14/41 (34.1%) | 40/41 (97.6%) |
| Eculizumab/Eculizumab | 0/78 (0%) | 26/78 (33.3%) | 70/78 (89.7%) |
| Eculizumab (Combined Total) | 0/119 (0%) | 40/119 (33.6%) | 110/119 (92.4%) |
| Event | Placebo/Eculizumab | Eculizumab/Eculizumab | Eculizumab (Combined Total) |
|---|---|---|---|
| Cholecystitis acuteHepatobiliary disorders | 2/41 | 1/78 | 3/119 |
| Urinary tract infectionInfections and infestations | 2/41 | 3/78 | 5/119 |
| Neuromyelitis optica spectrum disorderNervous system disorders | 2/41 | 3/78 | 5/119 |
| Pyelonephritis acuteInfections and infestations | 0/41 | 2/78 | 2/119 |
| UrosepsisInfections and infestations | 0/41 | 2/78 | 2/119 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/41 | 2/78 | 2/119 |
| Optic neuritisNervous system disorders | 1/41 | 2/78 | 3/119 |
| LymphadenopathyBlood and lymphatic system disorders | 1/41 | 0/78 | 1/119 |
| Irritable bowel syndromeGastrointestinal disorders | 1/41 | 0/78 | 1/119 |
| AstheniaGeneral disorders | 1/41 | 0/78 | 1/119 |
| Event | Placebo/Eculizumab | Eculizumab/Eculizumab | Eculizumab (Combined Total) |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 16/41 | 13/78 | 29/119 |
| HeadacheNervous system disorders | 12/41 | 15/78 | 27/119 |
| Upper respiratory tract infectionInfections and infestations | 11/41 | 17/78 | 28/119 |
| Urinary tract infectionInfections and infestations | 11/41 | 13/78 | 24/119 |
| InfluenzaInfections and infestations | 9/41 | 10/78 | 19/119 |
| DiarrhoeaGastrointestinal disorders | 8/41 | 6/78 | 14/119 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 8/41 | 15/78 | 23/119 |
| NauseaGastrointestinal disorders | 7/41 | 3/78 | 10/119 |
| CoughRespiratory, thoracic and mediastinal disorders | 7/41 | 5/78 | 12/119 |
| PyrexiaGeneral disorders | 6/41 | 12/78 | 18/119 |
The Extension Full Analysis Set consisted of all participants who had received at least 1 dose of eculizumab in Study ECU-NMO-302 and have a post-IP-infusion efficacy assessment.
| Age, Continuous(years) | Placebo/Eculizumab | Eculizumab/Eculizumab | Total |
|---|---|---|---|
| Mean | 46.0 ± 13.82 | 46.6 ± 13.77 | 46.4 ± 13.73 |
| Sex: Female, Male(Participants) | Placebo/Eculizumab | Eculizumab/Eculizumab | Total |
|---|---|---|---|
| Female | 36 | 74 | 110 |
| Male | 5 | 4 | 9 |
| Ethnicity (NIH/OMB)(Participants) | Placebo/Eculizumab | Eculizumab/Eculizumab | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 11 | 13 |
| Not Hispanic or Latino | 37 | 63 | 100 |
| Unknown or Not Reported | 2 | 4 | 6 |
| Race/Ethnicity, Customized(Participants) | Placebo/Eculizumab | Eculizumab/Eculizumab | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 13 | 32 | 45 |
| Black or African American | 7 | 3 | 10 |
| White | 21 | 40 | 61 |
| Other | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2015 to primary completion in Jul 2021, 78 months.
Results were first posted in Aug 2022, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eculizumab
Alexion Pharmaceuticals, Inc. →